NanoViricides, Inc. (NNVC) 10-Year Financial Performance & Capital Metrics

NNVC • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.Show more

Revenue $0
EBITDA -$9M -14.1%
Net Income -$9M -14.1%
EPS (Diluted) -0.63 +10.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.75% -58.3%
ROIC -113.96% -19.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 27.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.77%

ROCE

10Y Avg-49.03%

5Y Avg-54.42%

3Y Avg-69.2%

Latest-101.06%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	659.54K	662.95K	680.06K	695.91K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-659.54K	-662.95K	-680.06K	-695.91K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.01%	-0.03%	-0.02%	1%	-	-	-	-	-
Operating Expenses+	8.86M	9.6M	9.33M	8.66M	8M	8.74M	8.11M	8.94M	8.52M	9.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.83M	4.07M	4.5M	2.74M	3.3M	2.63M	2.33M	2.55M	3.08M	4.04M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.03M	5.53M	4.83M	5.92M	4.7M	6.11M	5.78M	6.39M	5.44M	5.55M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.86M	-9.6M	-9.33M	-8.66M	-8M	-8.74M	-8.11M	-8.94M	-8.52M	-9.59M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.25%	-0.08%	0.03%	0.07%	0.08%	-0.09%	0.07%	-0.1%	0.05%	-0.13%
EBITDA+	-8.2M	-8.94M	-8.65M	-7.96M	-7.3M	-8.04M	-7.39M	-8.2M	-7.76M	-8.85M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.21%	-0.09%	0.03%	0.08%	0.08%	-0.1%	0.08%	-0.11%	0.05%	-0.14%
D&A (Non-Cash Add-back)	659.54K	662.95K	680.06K	695.91K	699.72K	704.54K	723.33K	747.53K	759.01K	743.8K
EBIT	-8.86M	-9.6M	-9.27M	-8.66M	-8M	-8.74M	-8.1M	-8.59M	-8.24M	-9.47M
Net Interest Income+	-2.41M	-2.07M	-444.06K	55.5K	-76.59K	-76.06K	6.74K	354.89K	221.97K	124.83K
Interest Income	62.64K	60.95K	100.43K	55.5K	17.08K	9.35K	11.86K	355.83K	271.77K	124.83K
Interest Expense	2.47M	2.13M	544.49K	0	93.67K	85.41K	5.12K	938	49.81K	0
Other Income/Expense	-1.87M	-703.77K	761.71K	235.24K	-5.45M	-78.08K	6.74K	354.89K	221.97K	124.68K
Pretax Income+	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-179.75K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%	1%
Net Income+	-10.72M	-10.3M	-8.56M	-8.24M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-3.88%	0.04%	0.17%	0.04%	-0.63%	0.34%	0.08%	-0.06%	0.03%	-0.14%
Net Income (Continuing)	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.72	-3.43	-2.64	-2.30	-2.39	-0.81	-0.70	-0.74	-0.70	-0.63
EPS Growth %	-4.03%	0.08%	0.23%	0.13%	-0.04%	0.66%	0.14%	-0.06%	0.05%	0.1%
EPS (Basic)	-3.72	-3.43	-2.64	-2.30	-2.39	-0.81	-0.70	-0.74	-0.70	-0.63
Diluted Shares Outstanding	2.88M	3.01M	3.25M	3.59M	5.62M	10.9M	11.53M	11.63M	11.87M	15.12M
Basic Shares Outstanding	2.88M	3.01M	3.25M	3.59M	5.62M	10.9M	11.53M	11.63M	11.87M	15.12M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	24.38M	15.29M	7.32M	2.83M	13.99M	20.82M	14.42M	8.45M	4.97M	1.67M
Cash & Short-Term Investments	24.16M	15.1M	7.08M	2.56M	13.71M	20.52M	14.07M	8.15M	4.8M	1.56M
Cash Only	24.16M	15.1M	7.08M	2.56M	13.71M	20.52M	14.07M	8.15M	4.8M	1.56M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	12.25M	11.71M	11.22M	10.62M	9.93M	9.44M	9.08M	8.45M	7.85M	7.15M
Property, Plant & Equipment	11.76M	11.27M	10.84M	10.23M	9.54M	9.08M	8.69M	8.11M	7.51M	6.83M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	391.47K	383.2K	374.93K	366.66K	358.39K	350.12K	341.85K	333.58K	325.31K	317.04K
Long-Term Investments	3.52K	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	99.54K	58.93K	8.16K	29.19K	25.86K	3.52K	42.44K	14.36K	14.56K	2.44K
Total Assets+	36.63M	27M	18.55M	13.45M	23.91M	30.26M	23.49M	16.9M	12.82M	8.82M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.17%	-0.26%	-0.31%	-0.27%	0.78%	0.27%	-0.22%	-0.28%	-0.24%	-0.31%
Total Current Liabilities+	6.74M	4.67M	881.95K	2.85M	2.16M	351.15K	412.84K	534.25K	1.36M	1.31M
Accounts Payable	96.52K	135.79K	223.34K	309.89K	380.73K	200.02K	57.96K	157.06K	376.27K	1.28M
Days Payables Outstanding	53.42	74.76	119.87	162.54	-	-	-	-	-	-
Short-Term Debt	5.47M	3.96M	0	0	1.14M	95.31K	94.79K	0	0	0
Deferred Revenue (Current)	969.72K	541.37K	0	0	0	0	0	0	0	0
Other Current Liabilities	1.14M	539.58K	638.89K	2.53M	592.58K	0	214.4K	338.13K	958.97K	0
Current Ratio	3.62x	3.28x	8.30x	0.99x	6.49x	59.30x	34.92x	15.81x	3.66x	1.28x
Quick Ratio	3.62x	3.28x	8.30x	0.99x	6.49x	59.30x	34.92x	15.81x	3.66x	1.28x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.84M	2.02M	0	0	0	0	0	1.5M	0	0
Long-Term Debt	3.13M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.71M	2.02M	0	0	0	0	0	1.5M	0	0
Total Liabilities	13.59M	6.68M	881.95K	2.85M	2.16M	351.15K	412.84K	2.03M	1.36M	1.31M
Total Debt+	8.61M	3.96M	0	0	1.14M	95.31K	94.79K	0	0	0
Net Debt	-15.55M	-11.14M	-7.08M	-2.56M	-12.56M	-20.42M	-13.97M	-8.15M	-4.8M	-1.56M
Debt / Equity	0.37x	0.19x	-	-	0.05x	0.00x	0.00x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.59x	-4.51x	-17.13x	-	-85.37x	-102.38x	-1583.76x	-9534.61x	-170.98x	-
Total Equity+	23.05M	20.32M	17.66M	10.6M	21.76M	29.91M	23.08M	14.87M	11.46M	7.52M
Equity Growth %	-0.27%	-0.12%	-0.13%	-0.4%	1.05%	0.37%	-0.23%	-0.36%	-0.23%	-0.34%
Book Value per Share	7.99	6.76	5.44	2.95	3.87	2.74	2.00	1.28	0.97	0.50
Total Shareholders' Equity	23.05M	20.32M	17.66M	10.6M	21.76M	29.91M	23.08M	14.87M	11.46M	7.52M
Common Stock	58.18K	63.3K	69.17K	76.9K	9.08K	11.52K	116	116	131	166
Retained Earnings	-64.82M	-75.13M	-83.69M	-92.12M	-105.56M	-114.39M	-122.49M	-131.08M	-139.37M	-148.84M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-6.83M	-7.9M	-7.78M	-6.8M	-6.67M	-8.21M	-5.89M	-5.67M	-6.32M	-8.48M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.1%	-0.16%	0.02%	0.13%	0.02%	-0.23%	0.28%	0.04%	-0.11%	-0.34%
Net Income	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Depreciation & Amortization	659.54K	662.95K	680.06K	695.91K	699.72K	704.54K	723.33K	747.53K	759.01K	743.8K
Stock-Based Compensation	1.23M	1.6M	791.16K	532.32K	559.4K	405.59K	338.42K	214.18K	222.19K	223.35K
Deferred Taxes	-415.95K	-1.33M	-1.14M	-191.66K	5.24M	8.13K	0	-99.1K	0	0
Other Non-Cash Items	2.09M	1.95M	419.49K	17.39K	163.96K	30.2K	939.3K	257.1K	563	679
Working Capital Changes	336.64K	-485.86K	32.38K	567.71K	119.66K	-540.11K	214.56K	1.8M	996.88K	20.46K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	458.26K	-387.5K	-145.67K	802.87K	110.63K	-710.75K	40.8K	118.13K	705.82K	184.24K
Cash from Investing+	-476.37K	-164.98K	-241.82K	-73.79K	-8.64K	-238.76K	-324.35K	-151.71K	-156.56K	-56.96K
Capital Expenditures	-476.37K	-164.98K	-241.82K	-73.79K	-8.64K	-238.76K	-324.35K	-151.71K	-156.56K	-56.96K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	0	-1M	4.61M	2.35M	17.83M	15.26M	-234.72K	-94.79K	3.12M	5.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-4.61M	0	-12.19K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.31M	-8.06M	-8.02M	-6.88M	-6.67M	-8.45M	-6.22M	-5.82M	-6.47M	-8.54M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.44%	-0.1%	0.01%	0.14%	0.03%	-0.27%	0.26%	0.06%	-0.11%	-0.32%
FCF per Share	-2.53	-2.68	-2.47	-1.92	-1.19	-0.78	-0.54	-0.50	-0.55	-0.56
FCF Conversion (FCF/Net Income)	0.64x	0.77x	0.91x	0.83x	0.50x	0.93x	0.73x	0.66x	0.76x	0.90x
Interest Paid	0	0	0	0	0	0	0	0	0	149
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-39.12%	-47.52%	-45.09%	-58.34%	-83.11%	-34.15%	-30.6%	-45.27%	-63%	-99.75%
Return on Invested Capital (ROIC)	-88.63%	-86.37%	-70.78%	-69.73%	-69.58%	-70.2%	-65.43%	-84.77%	-95.46%	-113.96%
Debt / Equity	0.37x	0.19x	-	-	0.05x	0.00x	0.00x	-	-	-
Interest Coverage	-3.59x	-4.51x	-17.13x	-	-85.37x	-102.38x	-1583.76x	-9534.61x	-170.98x	-
FCF Conversion	0.64x	0.77x	0.91x	0.83x	0.50x	0.93x	0.73x	0.66x	0.76x	0.90x

Frequently Asked Questions

Growth & Financials

NanoViricides, Inc. (NNVC) grew revenue by 0.0% over the past year. Growth has been modest.

NanoViricides, Inc. (NNVC) reported a net loss of $8.1M for fiscal year 2025.

Dividend & Returns

NanoViricides, Inc. (NNVC) has a return on equity (ROE) of -99.7%. Negative ROE indicates the company is unprofitable.

NanoViricides, Inc. (NNVC) had negative free cash flow of $7.6M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

NanoViricides, Inc. (NNVC) 10-Year Financial Performance & Capital Metrics

NNVC • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $0
EBITDA -$9M -14.1%
Net Income -$9M -14.1%
EPS (Diluted) -0.63 +10.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.75% -58.3%
ROIC -113.96% -19.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 27.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.77%

ROCE

10Y Avg-49.03%

5Y Avg-54.42%

3Y Avg-69.2%

Latest-101.06%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	659.54K	662.95K	680.06K	695.91K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-659.54K	-662.95K	-680.06K	-695.91K	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.01%	-0.03%	-0.02%	1%	-	-	-	-	-
Operating Expenses+	8.86M	9.6M	9.33M	8.66M	8M	8.74M	8.11M	8.94M	8.52M	9.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.83M	4.07M	4.5M	2.74M	3.3M	2.63M	2.33M	2.55M	3.08M	4.04M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.03M	5.53M	4.83M	5.92M	4.7M	6.11M	5.78M	6.39M	5.44M	5.55M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.86M	-9.6M	-9.33M	-8.66M	-8M	-8.74M	-8.11M	-8.94M	-8.52M	-9.59M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.25%	-0.08%	0.03%	0.07%	0.08%	-0.09%	0.07%	-0.1%	0.05%	-0.13%
EBITDA+	-8.2M	-8.94M	-8.65M	-7.96M	-7.3M	-8.04M	-7.39M	-8.2M	-7.76M	-8.85M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.21%	-0.09%	0.03%	0.08%	0.08%	-0.1%	0.08%	-0.11%	0.05%	-0.14%
D&A (Non-Cash Add-back)	659.54K	662.95K	680.06K	695.91K	699.72K	704.54K	723.33K	747.53K	759.01K	743.8K
EBIT	-8.86M	-9.6M	-9.27M	-8.66M	-8M	-8.74M	-8.1M	-8.59M	-8.24M	-9.47M
Net Interest Income+	-2.41M	-2.07M	-444.06K	55.5K	-76.59K	-76.06K	6.74K	354.89K	221.97K	124.83K
Interest Income	62.64K	60.95K	100.43K	55.5K	17.08K	9.35K	11.86K	355.83K	271.77K	124.83K
Interest Expense	2.47M	2.13M	544.49K	0	93.67K	85.41K	5.12K	938	49.81K	0
Other Income/Expense	-1.87M	-703.77K	761.71K	235.24K	-5.45M	-78.08K	6.74K	354.89K	221.97K	124.68K
Pretax Income+	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-179.75K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%	1%
Net Income+	-10.72M	-10.3M	-8.56M	-8.24M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-3.88%	0.04%	0.17%	0.04%	-0.63%	0.34%	0.08%	-0.06%	0.03%	-0.14%
Net Income (Continuing)	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.72	-3.43	-2.64	-2.30	-2.39	-0.81	-0.70	-0.74	-0.70	-0.63
EPS Growth %	-4.03%	0.08%	0.23%	0.13%	-0.04%	0.66%	0.14%	-0.06%	0.05%	0.1%
EPS (Basic)	-3.72	-3.43	-2.64	-2.30	-2.39	-0.81	-0.70	-0.74	-0.70	-0.63
Diluted Shares Outstanding	2.88M	3.01M	3.25M	3.59M	5.62M	10.9M	11.53M	11.63M	11.87M	15.12M
Basic Shares Outstanding	2.88M	3.01M	3.25M	3.59M	5.62M	10.9M	11.53M	11.63M	11.87M	15.12M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	24.38M	15.29M	7.32M	2.83M	13.99M	20.82M	14.42M	8.45M	4.97M	1.67M
Cash & Short-Term Investments	24.16M	15.1M	7.08M	2.56M	13.71M	20.52M	14.07M	8.15M	4.8M	1.56M
Cash Only	24.16M	15.1M	7.08M	2.56M	13.71M	20.52M	14.07M	8.15M	4.8M	1.56M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	12.25M	11.71M	11.22M	10.62M	9.93M	9.44M	9.08M	8.45M	7.85M	7.15M
Property, Plant & Equipment	11.76M	11.27M	10.84M	10.23M	9.54M	9.08M	8.69M	8.11M	7.51M	6.83M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	391.47K	383.2K	374.93K	366.66K	358.39K	350.12K	341.85K	333.58K	325.31K	317.04K
Long-Term Investments	3.52K	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	99.54K	58.93K	8.16K	29.19K	25.86K	3.52K	42.44K	14.36K	14.56K	2.44K
Total Assets+	36.63M	27M	18.55M	13.45M	23.91M	30.26M	23.49M	16.9M	12.82M	8.82M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.17%	-0.26%	-0.31%	-0.27%	0.78%	0.27%	-0.22%	-0.28%	-0.24%	-0.31%
Total Current Liabilities+	6.74M	4.67M	881.95K	2.85M	2.16M	351.15K	412.84K	534.25K	1.36M	1.31M
Accounts Payable	96.52K	135.79K	223.34K	309.89K	380.73K	200.02K	57.96K	157.06K	376.27K	1.28M
Days Payables Outstanding	53.42	74.76	119.87	162.54	-	-	-	-	-	-
Short-Term Debt	5.47M	3.96M	0	0	1.14M	95.31K	94.79K	0	0	0
Deferred Revenue (Current)	969.72K	541.37K	0	0	0	0	0	0	0	0
Other Current Liabilities	1.14M	539.58K	638.89K	2.53M	592.58K	0	214.4K	338.13K	958.97K	0
Current Ratio	3.62x	3.28x	8.30x	0.99x	6.49x	59.30x	34.92x	15.81x	3.66x	1.28x
Quick Ratio	3.62x	3.28x	8.30x	0.99x	6.49x	59.30x	34.92x	15.81x	3.66x	1.28x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.84M	2.02M	0	0	0	0	0	1.5M	0	0
Long-Term Debt	3.13M	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	3.71M	2.02M	0	0	0	0	0	1.5M	0	0
Total Liabilities	13.59M	6.68M	881.95K	2.85M	2.16M	351.15K	412.84K	2.03M	1.36M	1.31M
Total Debt+	8.61M	3.96M	0	0	1.14M	95.31K	94.79K	0	0	0
Net Debt	-15.55M	-11.14M	-7.08M	-2.56M	-12.56M	-20.42M	-13.97M	-8.15M	-4.8M	-1.56M
Debt / Equity	0.37x	0.19x	-	-	0.05x	0.00x	0.00x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.59x	-4.51x	-17.13x	-	-85.37x	-102.38x	-1583.76x	-9534.61x	-170.98x	-
Total Equity+	23.05M	20.32M	17.66M	10.6M	21.76M	29.91M	23.08M	14.87M	11.46M	7.52M
Equity Growth %	-0.27%	-0.12%	-0.13%	-0.4%	1.05%	0.37%	-0.23%	-0.36%	-0.23%	-0.34%
Book Value per Share	7.99	6.76	5.44	2.95	3.87	2.74	2.00	1.28	0.97	0.50
Total Shareholders' Equity	23.05M	20.32M	17.66M	10.6M	21.76M	29.91M	23.08M	14.87M	11.46M	7.52M
Common Stock	58.18K	63.3K	69.17K	76.9K	9.08K	11.52K	116	116	131	166
Retained Earnings	-64.82M	-75.13M	-83.69M	-92.12M	-105.56M	-114.39M	-122.49M	-131.08M	-139.37M	-148.84M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-6.83M	-7.9M	-7.78M	-6.8M	-6.67M	-8.21M	-5.89M	-5.67M	-6.32M	-8.48M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.1%	-0.16%	0.02%	0.13%	0.02%	-0.23%	0.28%	0.04%	-0.11%	-0.34%
Net Income	-10.72M	-10.3M	-8.56M	-8.42M	-13.45M	-8.82M	-8.11M	-8.59M	-8.29M	-9.47M
Depreciation & Amortization	659.54K	662.95K	680.06K	695.91K	699.72K	704.54K	723.33K	747.53K	759.01K	743.8K
Stock-Based Compensation	1.23M	1.6M	791.16K	532.32K	559.4K	405.59K	338.42K	214.18K	222.19K	223.35K
Deferred Taxes	-415.95K	-1.33M	-1.14M	-191.66K	5.24M	8.13K	0	-99.1K	0	0
Other Non-Cash Items	2.09M	1.95M	419.49K	17.39K	163.96K	30.2K	939.3K	257.1K	563	679
Working Capital Changes	336.64K	-485.86K	32.38K	567.71K	119.66K	-540.11K	214.56K	1.8M	996.88K	20.46K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	458.26K	-387.5K	-145.67K	802.87K	110.63K	-710.75K	40.8K	118.13K	705.82K	184.24K
Cash from Investing+	-476.37K	-164.98K	-241.82K	-73.79K	-8.64K	-238.76K	-324.35K	-151.71K	-156.56K	-56.96K
Capital Expenditures	-476.37K	-164.98K	-241.82K	-73.79K	-8.64K	-238.76K	-324.35K	-151.71K	-156.56K	-56.96K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	0	-1M	4.61M	2.35M	17.83M	15.26M	-234.72K	-94.79K	3.12M	5.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-4.61M	0	-12.19K	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.31M	-8.06M	-8.02M	-6.88M	-6.67M	-8.45M	-6.22M	-5.82M	-6.47M	-8.54M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.44%	-0.1%	0.01%	0.14%	0.03%	-0.27%	0.26%	0.06%	-0.11%	-0.32%
FCF per Share	-2.53	-2.68	-2.47	-1.92	-1.19	-0.78	-0.54	-0.50	-0.55	-0.56
FCF Conversion (FCF/Net Income)	0.64x	0.77x	0.91x	0.83x	0.50x	0.93x	0.73x	0.66x	0.76x	0.90x
Interest Paid	0	0	0	0	0	0	0	0	0	149
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-39.12%	-47.52%	-45.09%	-58.34%	-83.11%	-34.15%	-30.6%	-45.27%	-63%	-99.75%
Return on Invested Capital (ROIC)	-88.63%	-86.37%	-70.78%	-69.73%	-69.58%	-70.2%	-65.43%	-84.77%	-95.46%	-113.96%
Debt / Equity	0.37x	0.19x	-	-	0.05x	0.00x	0.00x	-	-	-
Interest Coverage	-3.59x	-4.51x	-17.13x	-	-85.37x	-102.38x	-1583.76x	-9534.61x	-170.98x	-
FCF Conversion	0.64x	0.77x	0.91x	0.83x	0.50x	0.93x	0.73x	0.66x	0.76x	0.90x

Frequently Asked Questions

Growth & Financials

NanoViricides, Inc. (NNVC) grew revenue by 0.0% over the past year. Growth has been modest.

NanoViricides, Inc. (NNVC) reported a net loss of $8.1M for fiscal year 2025.

Dividend & Returns

NanoViricides, Inc. (NNVC) has a return on equity (ROE) of -99.7%. Negative ROE indicates the company is unprofitable.

NanoViricides, Inc. (NNVC) had negative free cash flow of $7.6M in fiscal year 2025, likely due to heavy capital investments.